Understanding how to control cell fate is crucial in biology, medical science and engineering. In this study, we introduce a method that uses an intracellular protein as a trigger for regulating human cell fate. The ON/OFF translational switches, composed of an intracellular protein L7Ae and its binding RNA motif, regulate the expression of a desired target protein and control two distinct apoptosis pathways in target human cells. Combined use of the switches demonstrates that a specific protein can simultaneously repress and activate the translation of two different mRNAs: one protein achieves both up- and downregulation of two different proteins/pathways. A genome-encoded protein fused to L7Ae controlled apoptosis in both directions (death or survival) depending on its cellular expression. The method has potential for curing cellular defects or improving the intracellular production of useful molecules by bypassing or rewiring intrinsic signal networks.
In human cells, the specific regulation of target protein production at the post-transcriptional level has a significant role in determining cellular phenotypes, such as growth, proliferation, differentiation or programmed cell death (apoptosis)1,2,3. For instance, several studies comparing the amounts of expressed mRNAs and proteins in eukaryotic cells have demonstrated that expression of an mRNA only weakly correlates with that of the corresponding protein, indicating that protein expression is regulated not only at the transcriptional level but also at multiple post-transcriptional steps, including translational regulation and mRNA/protein degradation1,4,5,6. Although many synthetic methods have been reported for controlling transcription7,8,9,10,11, only a few methods for controlling translation have been reported so far11,12,13,14,15,16.
A system that allows an endogenously expressed molecule such as a protein to control the expression level of a target gene would be especially advantageous. A method in which a specific protein produced in a cell can directly and quantitatively regulate the production of target protein(s) could be used to bypass or rewire intrinsic signalling networks and to construct novel cascades or feedback circuits for controlling cell functions (Fig. 1a)17,18.
Synthetic chimeric proteins have been used to rewire cell signalling pathways to control cell phenotype19,20,21. For example, signal transduction by the receptor tyrosine kinase ErbB2 was rewired by fusing SH2 or PTB domains of the adaptor proteins Grb2 and ShcA to the death effector domain of FADD (Fas-Associated protein with Death Domain)22. In this system, the chimeric adaptors relayed the signal from epidermal growth factor (EGF) to the caspase 8-dependent apoptotic pathway to induce cell death. However, the controllable signalling pathways are limited to those using the available adaptor proteins. It also remains unknown whether a protein expressed in cells can be used as a triggering signal for regulating the expression of a desired protein in these systems.
In this study, we report advanced protein-driven translational regulatory ON/OFF systems for controlling the fate of human cells (Fig. 1a,b). The design of the OFF system was based on our previously reported translational repression system15 consisting of an archaeal ribosomal protein, L7Ae, and its binding RNA motif, box C/D kink-turn (Kt)23. In the OFF system, L7Ae expressed in human cells directly and quantitatively inhibits the translation of a target gene. A new translational activation (ON) system triggered by L7Ae has also been developed for regulating the processing of short hairpin RNAs (shRNAs). We were able to efficiently control apoptosis in human cells with each system individually and in combination. In conclusion, we have shown here a new approach for determining human cell fate by using a specific genome-encoded protein that serves as an index of the cellular environment (Fig. 1a).
Quantitative translational repression in living cells
We first investigated whether we could observe quantitative translational control by L7Ae in individual living cells. Two plasmids were constructed: pKt-GFP-I-CFP, in which the mRNA contains the box C/D Kt motif incorporated upstream of the AUG codon of the EGFP coding sequence, and pdKt-GFP-I-CFP, which contains a defective Kt motif. For pKt-GFP-I-CFP, EGFP production is under the control of the expression of L7Ae because of the interaction between L7Ae and the Kt motif. As ECFP production from IRES is independent of L7Ae, the ratio of the EGFP and ECFP signals indicates the level of translational repression (Supplementary Fig. S1a). The red fluorescent protein (AsRed2) was fused with L7Ae (AsRed2-L7Ae) to quantify the expression level of L7Ae for normalization of the data. Overall translational repression efficiencies across the entire population of cells confirmed that the OFF system is highly efficient and selective (Supplementary Fig. S1b). We next analysed the efficiency in individual cells. The results indicate that EGFP production from the Kt-GFP-I-CFP mRNA was repressed quantitatively and selectively in individual cells depending on the expression level of L7Ae (Supplementary Fig. S1c). Thus, we conclude that the efficiency of translational regulation corresponds to the expression level of the input L7Ae protein.
Reprogramming cell death pathways with the OFF system
The OFF system was applied for controlling human cell fate by modulating the translation of apoptosis regulatory proteins (Fig. 1b). The mitochondrial-dependent apoptosis pathways were used to control intrinsic apoptosis pathways (Fig. 1b, Bcl-xL/Bim-dependent pathways) because the balance between proapoptotic (that is, Bim) and antiapoptotic (that is, Bcl-xL) Bcl-2 family proteins determines cell fate24. Namely, the control of apoptosis pathways by gene regulation requires strict expression balance between pro- and antiapoptotic proteins25. For instance, the leaky expression of a proapoptotic gene makes it difficult to suppress apoptosis, as it amplifies apoptosis signals by positive feedback mechanism26,27. To control apoptosis by L7Ae, we constructed the following three plasmids: pKt-Bcl-xL-I-GFP (an antiapoptotic agent), pdKt-Bcl-xL-I-GFP (a negative control plasmid containing a defective Kt) and a plasmid encoding Bim (pBim, a proapoptotic agent) (Fig. 2a, Supplementary Fig. S2). Western blot analysis showed that L7Ae expressed in HeLa cells efficiently represses the expression of Bcl-xL from pKt-Bcl-xL-I-GFP (Fig. 2b, lane 5), but has no effect on the defective Kt mutant, pdKt-Bcl-xL-I-GFP (Fig. 2b, lane 7). Flow cytometric analysis confirmed that expression of Bcl-xL from pKt- or pdKt-Bcl-xL-I-GFP efficiently repressed Bim-induced apoptosis in cells (Fig. 2c, lane 2 versus lane 3 or 5). In addition, L7Ae triggered an apoptosis-inducing signal in the corresponding cells by promoting the translational regulation of Bcl-xL. Expression of L7Ae induced apoptosis specifically in cells containing both pBim and pKt-Bcl-xL-I-GFP (Fig. 2c, lane 4; Supplementary Fig. S3). An analysis of cell morphology confirmed that L7Ae induced apoptosis by repressing Bcl-xL expression in target cells (Fig. 2d, left, middle picture), whereas the normal phenotype was observed for cells containing the control plasmid (Fig. 2d, right, middle picture). Thus, L7Ae expressed in cells containing Kt-Bcl-xL mRNA induces apoptosis by repressing the expression of Bcl-xL.
To demonstrate the modularity of the OFF switch, we constructed an alternative system to direct cell fate towards survival by regulating a mitochondria-independent apoptotic pathway (Fig. 1b, FADD-dependent pathway). The expression of FADD has a critical role in inducing apoptosis in this pathway (Fig. 1b, right; Supplementary Fig. S4)28. We attempted to downregulate apoptosis by repressing the production of FADD with the L7Ae system (Supplementary Fig. S5a). L7Ae downregulated apoptosis effectively and specifically by repressing translation of FADD derived from pKt-FADD plasmid (Supplementary Fig. S5b–f). These results indicate that by repressing the expression of either anti- or proapoptotic proteins, the OFF system can steer the apoptosis pathway towards death or survival, respectively.
Synthetic translational activation of a target mRNA
Like the OFF system, the protein-triggered translational activation system (ON system) should work as a 'protein–protein information converter' that transmits information carried by an input protein (for example, L7Ae) to the desired output protein (for example, Bcl-xL). Such converters are useful for bypassing intrinsic cell signalling pathways or constructing synthetic signalling pathways (Fig. 1)19,20. To construct the ON system in human cells, we designed and constructed a synthetic shRNA29,30,31 containing an siRNA and the Kt motif in its stem and loop regions, respectively (Figs 1 and 3a; Supplementary Fig. S6). We will refer to this construct as Kt-shRNA. In this system, the Kt-shRNA is designed to result in specific degradation of a target mRNA by RNA interference (RNAi). Conversely, cellularly expressed L7Ae binding to Kt-shRNA is expected to interfere with Dicer-dependent cleavage of the shRNA, resulting in L7Ae-controlled protection of the target mRNA (Fig. 3a).
Before performing cell fate control experiments, we confirmed that the Kt-shRNA, which targeted the EGFP gene for RNAi (Kt-Sh-GFP; Fig. 3b), interacted specifically with recombinant L7Ae in vitro (Fig. 3c). We observed that the catalytic activity of Dicer was efficiently blocked by the RNA–protein (RNP) interaction (Fig. 3d). Two shRNA-coding plasmids, pKt-Sh-GFP and the corresponding negative control plasmid, pdKt-Sh-GFP, containing a defective Kt, were tested to show that they effectively downregulated the expression of EGFP at both the protein and the mRNA levels (Figs 3e,f). As expected, L7Ae expressed in HeLa cells could upregulate EGFP expression by binding to pKt-Sh-GFP, but it did not affect the downregulation of EGFP expression by pdKt-Sh-GFP (Fig. 3f).
To regulate cell fate, we prepared three shRNA-coding plasmids that targeted the Bcl-xL gene: pSh-Bcl-xL (positive control), pKt-Sh-Bcl-xL and pdKt-Sh-Bcl-xL (Fig. 4a). L7Ae selectively inhibited the activity of Dicer on Kt-Sh-Bcl-xL RNA in vitro, but not on dKt-Sh-Bcl-xL RNA (Fig. 4b). Western blotting showed that transfection of pKt-Sh-Bcl-xL or pdKt-Sh-Bcl-xL repressed expression of Bcl-xL in cells after 24 h as effectively as the positive control, pSh-Bcl-xL (Fig. 4c, lanes 7 and 8). Conversely, L7Ae protected the expression of Bcl-xL from repression by pKt-Sh-Bcl-xL selectively and effectively (Fig. 4c, lane 5). The results indicate that the interaction between L7Ae and Kt-shRNA inhibits RNAi activity, which results in translation of the protected target mRNA.
The ON system was used to control cell fate by activating Bcl-xL translation in the presence of L7Ae. Flow cytometric (Fig. 4d, lane 4) and cell morphology (Fig. 4e, left, bottom picture) analyses showed that the system repressed Bim-induced apoptosis by activating Bcl-xL expression (Fig. 1b). Taken together, the data indicate that the synthetic translational ON and OFF systems can each control cell fate in the desired direction (death or survival) by modulating translation of the target mRNAs.
Simultaneous control of cell fate by both ON and OFF systems
We next attempted to simultaneously repress the translation of one mRNA and activate expression of a second mRNA in human cells by using L7Ae. Plasmids encoding AsRed2, designed to serve as a repressible gene (AsRed2-OFF), and EGFP, designed to serve as an activating gene (EGFP-ON), were constructed. L7Ae expression simultaneously and selectively repressed the translation of AsRed2 and activated EGFP, which we confirmed by flow cytometry (Figs 5a,b) and fluorescence microscopy (Fig. 5c). The results indicate that a single protein simultaneously represses and activates translation of two different mRNAs in human cell.
The combined use of the ON/OFF systems was tested for controlling apoptotic pathways in human cells. The OFF and ON switches were designed to repress proapoptotic Bim (Bim-OFF) and to activate antiapoptotic Bcl-xL (Bcl-xL-ON), respectively (Fig. 1b). As expected, L7Ae simultaneously repressed Bim expression and activated Bcl-xL expression to successfully modulate apoptosis (Fig. 6a, lane 3; Fig. 6b, top left). We were able to unidirectionally control human cell fate by appropriately connecting the two systems to the existing signalling networks.
Control of apoptosis by a protein encoded in genome
Finally, we investigated to see whether a protein of interest encoded in the genome quantitatively controls apoptosis pathways as a function of the protein expression. The insertion of L7Ae into the genome allows us to use L7Ae as a molecular tag for a protein of interest. As a pilot system, we attempted to quantitatively regulate apoptosis by controlling the expression level of an input protein (L7Ae-tagged red fluorescent protein: DsRed-L7Ae) encoded in the genome. A stable cell line (T-REx HeLa) was used for the conditional expression of DsRed-L7Ae in the presence of tetracycline. Western blotting analysis confirmed that the repression of Bcl-xL production depends quantitatively on the expression of DsRed-L7Ae (Fig. 7a). Moreover, apoptosis of the target cells was induced by the expression of DsRed-L7Ae in a dose-dependent manner (Fig. 7b). We were also able to repress apoptosis by controlling FADD expression by using DsRed-L7Ae expressed from the genome (Supplementary Fig. S7). Thus, it seems certain that a specific protein encoded in the genome can drive the translational regulatory systems to control cell fate.
In this study, we have shown that the RNP switch containing the L7Ae–Kt RNP interaction motif enables the control of human cell phenotype. A specific protein (L7Ae or L7Ae-tagged protein of interest) expressed in cells repressed and activated translation of specific mRNAs coding the proteins (that is, Bcl-xL, Bim, FADD) involved in the signal-transduction cascades. Moreover, the protein-driven ON/OFF systems can control the intrinsic apoptosis signalling circuits (that is, mitochondria-dependent and -independent apoptosis pathways) to determine cell phenotype (cell death) (Figs 1a,b). The strict apoptotic control in this study is attributed to the efficient gene regulation by the RNP switches (Figs 2,4 and 5; Supplementary Fig. S1), indicating that it serves as a versatile switch in other applications. As a pilot system, a protein of interest fused to L7Ae that is integrated in the genome quantitatively controlled apoptosis pathways (Fig. 7, Supplementary Fig. S7), indicating that it is feasible to construct a system for controlling phenotype of cell as a function of changes in the cellular environment (that is, expression of a specific protein) in general (Fig. 1a).
Small molecules, such as tetracycline or theophylline, have been used as triggers for synthetic translational regulation. The most popular system using RNA aptamers for theophylline has been used to determine the activation (ON) or repression (OFF) of gene expression in bacteria and yeast cells12,32,33. Efficient synthetic genetic switches triggered by the small molecule have also been constructed by combining RNAi regulatory systems with repressor proteins in mammalian cells34. These methods are versatile and universally applicable. However, the control of cell function depending on the expression level of a particular gene of interest is extremely difficult by using a small molecule as an input signal.
Our protein-driven RNP switches are advantageous for the use in the signal-transduction cascades because protein molecules can be used as both input and output signals that is impossible for small molecule-based systems. For instance, an L7Ae–Kt interaction-based translational auto-feedback system could allow the sophisticated control of protein production depending on the cellular environment in a manner similar to naturally occurring translational feedback systems35. In our preliminary experiments, cellularly expressed L7Ae modulated its own translation level by binding to the Kt motif of the mRNA (Stapleton, J.A. et al., unpublished data). Thus, the ON/OFF switch could serve as a unique tool for accurately controlling cell fate because expression levels from particular mRNAs can vary in a spatiotemporal manner36 to induce a variety of cell phenotypes37.
Proteins other than L7Ae are potentially usable as new regulators for the system as follows: (1) The L7Ae protein could be used to tag other proteins of interest, and (2) a variety of RNA–protein binding motifs, including naturally occurring and in vitro-selected RNA aptamers, could be used for constructing new translational switches38. RNP interaction motifs can be seen as a new molecular resource for constructing libraries of interoperable components and modules39. Accordingly, development of a set of new RNP interaction motifs could be useful for next-generation and real-world application of synthetic gene networks9,15,39,40.
For instance, in vitro-selected aptamers could directly sense the expression of target marker proteins (for example, Bcl-xL, the expression level of which is known to be upregulated in certain cancer cells), and control the expression of the desired output proteins (for example, activation of a cell killer gene; Supplementary Fig. S8). Thereby, the switch could induce apoptosis in the target cancer cells. As another example, our RNP switches could be used for controlling the expression of multiple genes to produce useful molecules40,41, because the switches simultaneously repress and activate translation of different mRNAs as a function of the expression of specific proteins in living cells. The combined use of our RNP switch and other established regulatory systems based on transcriptional control42, modular engineering of chimeric proteins19,43 or small molecule-based riboswitches12,32,33,44,45,46 could further enhance the efficacy of the system when multiple actions are required to assure the outcome.
Cell culture and treatments
HeLa cells and HeLa-GFP cells were cultured at 37 °C in 5% CO2 in DMEM/F-12 (Dulbecco's modified Eagle's medium: Nutrient Mixture F-12) 1:1 mixture (Invitrogen), supplemented with an antibiotic solution (A5955, Sigma) and 10% calf bovine serum (CBS, MP Bioscience) or fetal bovine serum (CCB). HeLa-GFP cells were additionally supplemented with 50 μg ml−1 of Hygromycin B (Invitrogen). The DsRed-L7Ae-inducible cell line (T-REx HeLa-DsRed-L7Ae) was established previously15 as follows. T-REx HeLa cells (Invitrogen), cultured in fresh medium supplemented with 10% CBS (#2001H, MP Biomedicals), were transfected with pcDNA4/TO/DsRed-L7 containing the tetracycline-regulatable promoter and the DsRedM-L7Ae gene. After 24 h, the medium was replaced with fresh medium supplemented with 10% CBS, 5 μg ml−1 blasticidin (Invivogen) and 100–200 μg ml−1 zeocin (Invitrogen) for selection. The cells were cultured in selective medium every 3–4 days until foci could be identified. The selected cells were cloned using a cell sorter (FACS Aria, BD Biosciences). The clone exhibiting the highest expression level of DsRedM-L7Ae in the presence of Tet was confirmed by western blotting and named H5. The H5 cells were cultured in DMEM/F-12 supplemented with 10% CBS, 5 μg ml−1 blasticidin and 150 μg ml−1 zeocin.
Cells were plated into appropriate multi-well plates. After 1 day, the 70–90% confluent cells were transfected with plasmids using Lipofectamine 2000 according to the standard protocols included in the Lipofectamine 2000 kit (Invitrogen). After 4 h of transfection, the medium was replaced with fresh medium if needed.
All DNA templates and primers were purchased from Hokkaido System Science or Gene Design. PCR amplifications were carried out using Ex Taq DNA polymerase (TAKARA BIO) or KOD-PLUS-DNA polymerase (TOYOBO).
Apoptotic and dead cells were stained with Pacific Blue-labelled annexin V according to the standard protocols of the Vybrant Apoptosis Assay Kit #14 (Invitrogen). Dead cells were additionally stained by 7-AAD (Invitrogen) if needed. The stained cells were analysed on a FACS Aria. A 405 nm semiconductor laser was used for excitation of the Pacific Blue, and a 488 nm laser was used for EGFP, DsRedM, AsRed2 and 7-AAD. The 450/40 nm, 530/30 nm and 695/40 nm bandpass filters were used for collection of the fluorescent signals from Pacific Blue, EGFP and 7-AAD, respectively. When EGFP and DsRedM (or AsRed2) were expressed simultaneously, a 695/40 nm bandpass filter was used for the signals from DsRedM (or AsRed2); otherwise, a 616/23 nm bandpass filter was used. The remaining cells were collected and stored at −20 °C for analysis by western blotting, if needed.
Translational repression assay of apoptosis regulatory proteins
For western blotting analysis of repression of Bcl-xL in cells, HeLa cells (1×105 per well) were seeded onto 12-well plates. pL7Ae (0.4 μg) and pKt-Bcl-xL-I-GFP (or dKt-Bcl-xL-I-GFP, 0.2 μg) were co-transfected into HeLa cells. A blank plasmid, pcDNA that stands for pcDNA3.1-MycHisA (Invitrogen), was used as a control. Twenty-four hours after transfection, the cells were collected by trypsinization and Bcl-xL was detected using an anti-Bcl-xL antibody. For analysis of apoptosis regulated by Bcl-xL and Bim, HeLa cells were co-transfected as described above, except that the cells were additionally co-transfected with 0.2 μg of pBim. After 24 h, collected cells were stained by Pacific Blue-labelled annexin V and 7-AAD and analysed on a FACS Aria. Only EGFP-positive cells were analysed to eliminate debris, dust or untransfected cells. Pacific Blue-positive cells were considered dead.
For quantitative regulation of apoptosis, the DsRed-L7Ae-inducible cell line (3×105 per well) was used instead of HeLa cells. Cells were co-transfected with 0.4 μg of pKt-Bcl-xL-I-GFP (or dKt-Bcl-xL-I-GFP) and 0.4 μg of pBim using 2 μl Lipofectamine 2000. After 4 h, expression of DsRed-L7Ae was induced by tetracycline (Invitrogen) at 0–15 ng ml−1. After 24 h, the cells were stained by Pacific Blue-labelled annexin V and analysed on the FACS Aria.
To confirm proapoptotic activities of FADD and its pathway, DsRed-L7Ae-inducible cell lines (3×105 per well) were seeded onto 12-well plates. The cells were co-transfected with 0.9 μg of pKt-FADD and 0.4 μg of pEGFP-N1 in the presence or absence of 20 μM of Z-V-FMK (Sigma). For analysis of apoptosis regulated by FADD, HeLa cells (5×105 per well) were seeded onto six-well plates. The cells were co-transfected with 0.5 μg of pKt-FADD (or pdKt-FADD) and 1 μg of pL7Ae and collected after 24 h. Expression of FADD in the cells was detected by western blotting using an anti-c-Myc antibody. To eliminate untransfected cells, cells were additionally co-transfected with 0.2 μg of pEGFP-N1 for flow cytometric analysis. The collected cells were stained by Pacific Blue-labelled annexin V and 7-AAD and subjected to flow cytometric analysis. Pacific Blue-positive cells were considered dead.
Dicer-dependent shRNA in vitro cleavage assay
Kt-Sh-Bcl-xL or dKt-Sh-Bcl-xL (40 nM) and the purified L7Ae protein (0, 800 or 1,600 nM) were mixed with 1 μl of 10 mM ATP, 0.5 μl of 50 mM MgCl2, 4 μl of Dicer Reaction Buffer (Genlantis), 2 μl of 0.5 U μl−1 Recombinant Human Dicer Enzyme (Genlantis), and water (up to 10 μl). The mixtures were incubated at 37 °C for 14 h and incubation was stopped with 2 μl of Dicer Stop Solution. The mixtures were separated by 15% native PAGE at 4 °C for 50 min and the gel was stained with SYBER-Green (TAKARA BIO). The fluorescence of the stained RNA was detected by FLA-7000 (Fujifilm) (Fig. 4b). Kt-Sh-GFP and dKt-Sh-GFP were also analysed using the above procedure (Fig. 3d).
Translational activation assay of Bcl-xL
To examine the re-activation efficiency of Bcl-xL translation triggered by Kt-L7Ae binding, we co-transfected HeLa cells (3×105 per well) grown for 1 day in 12-well plates with pBcl-xL, p(d)Kt-Sh-Bcl-xL and pL7Ae using 2.5 μl of Lipofectamine 2000. Twenty-four hours after transfection, Bcl-xL was quantified by western blotting analysis. To examine the efficiency of cell fate determination through the control of Bcl-xL translation triggered by Kt-L7Ae binding, we co-transfected HeLa cells (0.5×105 per well) grown for 1 day in 24-well plates with 0.2 μg of pBim, 0.2 μg of pBcl-xL, 0.3 μg of p(d)Kt-Sh-Bcl-xL and 0.2 μg of pAsRed2-L7Ae using 1.25 μl of Lipofectamine 2000. Twenty-four hours after transfection, following a cell morphology analysis, the cells and medium were collected and stained with Pacific Blue-labelled annexin V as described in the apoptosis assay. The populations of apoptotic and dead cells, which exhibited high fluorescence intensity of Pacific Blue, were analysed using a flow cytometer. To eliminate abnormal cells, those cells whose fetal calf serum and Superconducting Super Collider signal scopes were identical to those of untreated HeLa cells were selected for the calculation of mean intensities. The red fluorescence of AsRed2-L7 was used as a marker for co-transfected cells. pSh-Bcl-xL and pSh-N were used for positive and negative controls of Bcl-xL knockdown, respectively.
Synchronized control of ON/OFF translational switches
For the synchronized control of AsRed2-OFF and EGFP-ON switches triggered by Kt-L7Ae binding in the same cells, we co-transfected HeLa cells (0.8×105 per well) grown for 1 day in 24-well plates with 0, 0.05, 0.1, 0.2, 0.3 μg of pL7Ae and pcDNA (total amount 0.3 μg), 0.1 μg of pEGFP, 0.3 μg of p(d)Kt-Sh-GFP and 0.1 μg of p(d)Kt-AsRed2-I-CFP with 1.5 μl of Lipofectamine 2000. Transfection for fluorescent microscopic analysis was performed similarly, but with the replacement of p(d)Kt-AsRed2-I-CFP with p(d)Kt-AsRed2. Twenty-four hours after transfection, cells and medium were collected and re-suspended in medium. To measure the EGFP and AsRed2 fluorescence intensities, the CFP-expressing cells (as a positive control for the transfected cells) were analysed by a flow cytometer. The abnormal cells were eliminated as described in the translational activation assay. For the simultaneous control of Bim repression and Bcl-xL activation by mixing the Kt-L7Ae OFF and ON switches, we co-transfected HeLa cells (1.0×105 per well) grown for 1 day in 24-well plates with 0.2 μg of pBcl-xL, 0.2 μg of pAsRed2-L7Ae, 0.2 μg of p(d)Kt-Bim and 0.3 μg of p(d)Kt-Sh-Bcl-xL (the total amount of transfected plasmids was compensated with pcDNA up to 0.9 μg) with 1.25 μl of Lipofectamine 2000. Twenty-four hours after transfection, following cell morphology analysis, the cells and medium were collected and stained with Pacific Blue-labelled annexin V as described in the apoptosis assay. The populations of apoptotic and dead cells, which exhibited high fluorescence intensity of Pacific Blue, were analysed using a flow cytometer. The red fluorescence of AsRed2-L7 was used as a marker for co-transfected cells.
How to cite this article: Saito, H. et al. Synthetic human cell fate regulation by protein-driven RNA switches. Nat. Commun. 2:160 doi: 10.1038/ncomms1157 (2011).
Lu, R. et al. Systems-level dynamic analyses of fate change in murine embryonic stem cells. Nature 462, 358–362 (2009).
Keene, J. D. RNA regulons: coordination of post-transcriptional events. Nat. Rev. Genet. 8, 533–543 (2007).
Sonenberg, N. & Hinnebusch, A. G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 136, 731–745 (2009).
Gygi, S. P., Rochon, Y., Franza, B. R. & Aebersold, R. Correlation between protein and mRNA abundance in yeast. Mol. Cell Biol. 19, 1720–1730 (1999).
Brockmann, R., Beyer, A., Heinisch, J. J. & Wilhelm, T. Posttranscriptional expression regulation: what determines translation rates? PLoS Comput. Biol. 3, e57 (2007).
Houseley, J. & Tollervey, D. The many pathways of RNA degradation. Cell 136, 763–776 (2009).
You, L., Cox, R. S., Weiss, R. & Arnold, F. H. Programmed population control by cell-cell communication and regulated killing. Nature 428, 868–871 (2004).
Weber, W. & Fussenegger, M. Engineering of synthetic mammalian gene networks. Chem. Biol. 16, 287–297 (2009).
Purnick, P. E. & Weiss, R. The second wave of synthetic biology: from modules to systems. Nat. Rev. Mol. Cell Bio. 10, 410–422 (2009).
Elowitz, M. B. & Leibler, S. A synthetic oscillatory network of transcriptional regulators. Nature 403, 335–338 (2000).
Gardner, T. S., Cantor, C. R. & Collins, J. J. Construction of a genetic toggle switch in Escherichia coli. Nature 403, 339–342 (2000).
Win, M. N., Liang, J. C. & Smolke, C. D. Frameworks for programming biological function through RNA parts and devices. Chem. Biol. 16, 298–310 (2009).
Paraskeva, E., Atzberger, A. & Hentze, M. W. A translational repression assay procedure (TRAP) for RNA-protein interactions in vivo. Proc. Natl Acad. Sci. USA 95, 951–956 (1998).
Nie, M. & Htun, H. Different modes and potencies of translational repression by sequence-specific RNA-protein interaction at the 5′-UTR. Nucleic Acids Res. 34, 5528–5540 (2006).
Saito, H. et al. Synthetic translational regulation by an L7Ae-kink-turn RNP switch. Nat. Chem. Biol. 6, 71–78 (2010).
Isaacs, F. J. et al. Engineered riboregulators enable post-transcriptional control of gene expression. Nat. Biotechnol. 22, 841–847 (2004).
Dueber, J. E. et al. Synthetic protein scaffolds provide modular control over metabolic flux. Nat. Biotechnol. 27, 753–759 (2009).
Atsumi, S. & Liao, J. C. Metabolic engineering for advanced biofuels production from Escherichia coli. Curr. Opin. Biotechnol. 19, 414–419 (2008).
Bashor, C. J., Horwitz, A. A., Peisajovich, S. G. & Lim, W. A. Rewiring cells: synthetic biology as a tool to interrogate the organizational principles of living systems. Annu. Rev. Biophys. 39, 515–537 (2010).
Kiel, C., Yus, E. & Serrano, L. Engineering signal transduction pathways. Cell 140, 33–47 (2010).
Yeh, B. J. et al. Rewiring cellular morphology pathways with synthetic guanine nucleotide exchange factors. Nature 447, 596–600 (2007).
Howard, P. L. et al. Redirecting tyrosine kinase signaling to an apoptotic caspase pathway through chimeric adaptor proteins. Proc. Natl Acad. Sci. USA 100, 11267–11272 (2003).
Rozhdestvensky, T. S. et al. Binding of L7Ae protein to the K-turn of archaeal snoRNAs: a shared RNA binding motif for C/D and H/ACA box snoRNAs in Archaea. Nucleic Acids Res. 31, 869–877 (2003).
Liu, X. et al. The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. Immunity 19, 341–352 (2003).
Opferman, J. T. & Korsmeyer, S. J. Apoptosis in the development and maintenance of the immune system. Nat. Immunol. 4, 410–415 (2003).
Chen, D. & Zhou, Q. Caspase cleavage of BimEL triggers a positive feedback amplification of apoptotic signaling. Proc. Natl Acad. Sci. USA 101, 1235–1240 (2004).
Kirsch, D. G. et al. Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J. Biol. Chem. 274, 21155–21161 (1999).
Chinnaiyan, A. M., O'Rourke, K., Tewari, M. & Dixit, V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81, 505–512 (1995).
An, C.- I., Trinh, V. B. & Yokobayashi, Y. Artificial control of gene expression in mammalian cells by modulating RNA interference through aptamer-small molecule interaction. RNA 12, 710–716 (2006).
Beisel, C. L., Bayer, T. S., Hoff, K. G. & Smolke, C. D. Model-guided design of ligand-regulated RNAi for programmable control of gene expression. Mol. Syst. Biol. 4, 224 (2008).
Tuleuova, N. et al. Modulating endogenous gene expression of mammalian cells via RNA-small molecule interaction. Biochem. Biophys. Res. Commun. 376, 169–173 (2008).
Topp, S. & Gallivan, J. P. Emerging applications of riboswitches in chemical biology. ACS Chem. Biol. 5, 139–148 (2010).
Edwards, T. E., Klein, D. J. & Ferré-D'Amaré, A. R. Riboswitches: small-molecule recognition by gene regulatory RNAs. Curr. Opin. Struct. Biol. 17, 273–279 (2007).
Deans, T. L., Cantor, C. R. & Collins, J. J. A tunable genetic switch based on RNAi and repressor proteins for regulating gene expression in mammalian cells. Cell 130, 363–372 (2007).
Babitzke, P., Baker, C. S. & Romeo, T. Regulation of translation initiation by RNA binding proteins. Annu. Rev. Microbiol. 63, 27–44 (2009).
Meignin, C. & Davis, I. Transmitting the message: intracellular mRNA localization. Curr. Opin. Cell Biol. 22, 112–119 (2010).
Niwa, H., Miyazaki, J. & Smith, A. G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat. Genet. 24, 372–376 (2000).
Saito, H. & Inoue, T. Synthetic biology with RNA motifs. Int. J. Biochem. Cell Biol. 41, 398–404 (2009).
Saito, H. & Inoue, T. RNA and RNP as new molecular parts in synthetic biology. J. Biotechnol. 132, 1–7 (2007).
Lu, T. K., Khalil, A. S. & Collins, J. J. Next-generation synthetic gene networks. Nat. Biotechnol. 27, 1139–1150 (2009).
Khalil, A. S. & Collins, J. J. Synthetic biology: applications come of age. Nat. Rev. Genet. 11, 367–379 (2010).
Gossen, M., Bonin, A. L. & Bujard, H. Control of gene activity in higher eukaryotic cells by prokaryotic regulatory elements. Trends Biochem. Sci. 18, 471–475 (1993).
Zeke, A., Lukács, M., Lim, W. A. & Reményi, A. Scaffolds: interaction platforms for cellular signalling circuits. Trends Cell Biol. 19, 364–374 (2009).
Chen, Y. Y., Jensen, M. C. & Smolke, C. D. Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systems. Proc. Natl Acad. Sci. USA 107, 8531–8536 (2010).
Ausländer, S., Ketzer, P. & Hartig, J. S. A ligand-dependent hammerhead ribozyme switch for controlling mammalian gene expression. Mol. BioSyst. 6, 807–814 (2010).
Kötter, P. et al. A fast and efficient translational control system for conditional expression of yeast genes. Nucleic Acids Res. 37, e120 (2009).
We thank S. Yonehara (Kyoto University) for providing us with the FADD gene and for helpful discussions, T. Suzuki and T. Katoh (The University of Tokyo) for providing us with the shRNA-GFP and HeLa-GFP cells, A. Huttenhofer (Innsbruck Medical University, Biocenter) and T.S. Rozhdestvensky (University of Muenster) for providing the L7Ae plasmid, S. Shimizu (Osaka University) and Y. Shirakata for providing the Bcl-xL plasmid, and T. Nakamura (Cancer Institute, JAPAN) and D.C. Huang (The Walter and Eliza Hall Institute of Medical Research) for providing the Bim plasmid. We also thank J.A. Stapleton (Kyoto University) for critical reading of the manuscript. This work was supported by The Uehara Memorial Foundation (H.S.) and the International Cooperative Research Project (ICORP), JST (H.S., T.I.), and part of this work was supported by a grant from the New Energy and Industrial Technology Development Organization (NEDO) (09A02021a) (H.S.).
The authors declare no competing financial interests.
About this article
Cite this article
Saito, H., Fujita, Y., Kashida, S. et al. Synthetic human cell fate regulation by protein-driven RNA switches. Nat Commun 2, 160 (2011). https://doi.org/10.1038/ncomms1157
Caliciviral protein-based artificial translational activator for mammalian gene circuits with RNA-only delivery
Nature Communications (2020)
Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment
Nature Communications (2018)
Nature Communications (2013)
Nature Communications (2013)